CHMP meeting on 8 September 2010 to discuss Avandia and Pandemrix
03/09/2010 - The Committee for Medicinal Products for Human Use (CHMP) is meeting on Wednesday 8 September to discuss the ongoing benefit-risk review of the rosiglitazone-containing medicines Avandia, Avandamet and Avaglim.
Because of the complexity of the data being assessed, the Committee is holding this additional meeting outside of its usual monthly schedule. This will allow the CHMP to prepare for its next scheduled meeting of 20-23 September 2010, when it expects to finalise the review of rosiglitazone.
The CHMP will also be taking the opportunity to discuss its ongoing investigation into whether there is a risk of narcolepsy with the influenza vaccine Pandemrix.
After the meeting, the Agency will make public the next steps agreed by the Committee.
How useful is this page?
Average rating:Based on 2 ratings
Add your rating:
- See all ratings
0 ratings0 ratings1 ratings0 ratings1 ratings
- Avandia: EPAR
- Avaglim: EPAR
- Avandamet: EPAR
- European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim (22/07/2010)
- European Medicines Agency starts review of rosiglitazone-containing medicines (09/07/2010)
- Pandemrix: EPAR
- European Medicines Agency starts review of Pandemrix (27/08/2010)
Monika Benstetter or Sabine Haubenreisser
Tel. +44 (0)20 7418 8427